USPTO Art Unit 1646 Prosecution Statistics

Art Unit Information

Art Unit: 1646
Group: 1640
Tech Center: 1600
Total Cases: 12,640
Last Active: July 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19276860COMPOSITIONS AND METHODS RELATED TO GPRC5D BINDING AGENTS AND VARIANTS THEREOFJuly 2025October 2025Allow300NoNo
19243022IL-18/IL-23 MULTISPECIFIC ANTIGEN BINDING PROTEINSJune 2025February 2026Allow710NoNo
19171920LIPID NANOPARTICLE FORMULATIONS AND COMPOSITIONSApril 2025January 2026Abandon910NoNo
19081340PROTEASE-CLEAVABLE SUBSTRATES AND METHODS OF USE THEREOFMarch 2025January 2026Allow1011NoNo
19073422CD142 ANTIBODIES, ANTIBODY-DRUG CONJUGATES, PREPARATIONS AND USES THEREOFMarch 2025August 2025Allow510NoNo
19064325CD4+ T CELLS EXPRESSING IL-10 AND CHIMERIC ANTIGEN RECEPTORS AND USES THEREOFFebruary 2025November 2025Allow920YesNo
19064273ANTI-CEACAM5 ANTIBODY DRUG CONJUGATESFebruary 2025September 2025Allow610NoNo
19064618MODIFIED K562 FEEDER CELL LINE EXPRESSING FACTORS THAT ENHANCE THE ACTIVATION AND PROLIFERATION OF NATURAL KILLER CELLS AND A METHOD FOR ITS PRODUCTIONFebruary 2025March 2026Allow1321NoNo
19063190COMPOSITIONS TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND METHODS FOR MAKING AND USING THE SAMEFebruary 2025June 2025Allow310NoNo
19063195COMPOSITIONS TARGETING EPIDERMAL GROWTH FACTOR RECEPTOR AND METHODS FOR MAKING AND USING THE SAMEFebruary 2025August 2025Allow610NoNo
19035354ANTI-TRANSFERRIN RECEPTOR ANTIBODIES, CONJUGATES THEREOF, AND USES THEREOFJanuary 2025September 2025Allow810YesNo
19011114MULTI-DOMAIN MOLECULESJanuary 2025March 2026Allow1411YesNo
18999104TREM2 STABILIZING ANTIBODIESDecember 2024December 2025Allow1210YesNo
18957324BISPECIFIC ANTIBODY-CAMPTOTHECIN DRUG CONJUGATE AND PHARMACEUTICAL USE THEREOFNovember 2024July 2025Allow811NoNo
18953634METHODS AND COMPOSITIONS FOR DOSING OF ALLOGENEIC CHIMERIC ANTIGEN RECEPTOR T CELLSNovember 2024November 2025Allow1220NoNo
18919082COMPOSITIONS FOR TREATING CANCEROctober 2024June 2025Allow811NoNo
18914023ANTI-TISSUE FACTOR ANTIBODIES AND ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI-TISSUE FACTOR ANTIBODIES OR ANTIBODY CONJUGATES, AND METHODS OF MAKING AND USING ANTI-TISSUE FACTOR ANTIBODIES AND ANTIBODY CONJUGATESOctober 2024September 2025Allow1121YesNo
18904628ANTIBODY DRUG CONJUGATE (ADC) TARGETING NECTIN 4 AND COMPRISING AN EXATECAN PAYLOADOctober 2024July 2025Allow920YesNo
18897951BISPECIFIC ANTIBODIES TARGETING PD1 AND VEGFSeptember 2024June 2025Allow810NoNo
18290171ANTI-TIGIT ANTIBODIES AND USE THEREOFSeptember 2024October 2025Allow2320YesNo
18896098ANTIBODY-DRUG COMPLEX CONTAINING TOLL-LIKE RECEPTOR 7/8 DUAL AGONIST COMPOUNDSeptember 2024March 2025Allow510NoNo
18844818ANTIBODY-DRUG CONJUGATES AND THEIR USESSeptember 2024December 2025Allow1510NoNo
18802353COMPOUND COMPRISING FC-BINDING UNIT, AND CONJUGATE PREPARED USING SAMEAugust 2024January 2025Allow610NoNo
18792921IgE BINDING PROTEINS AND USES THEREOFAugust 2024December 2024Allow501YesNo
18787110IMMOBILIZED ENDOGLYCOSIDASE FUSION PROTEIN AND USE THEREOFJuly 2024April 2025Allow921NoNo
18781928CYTOKINE ASSOCIATED TUMOR INFILTRATING LYMPHOCYTES COMPOSITIONS AND METHODSJuly 2024December 2025Abandon1720NoYes
18777688METHOD FOR IMPROVING CELL ADHESION WITH SMECTITE CLAYJuly 2024October 2024Allow210NoNo
18777706METHOD OF INCREASING CELL ADHESION WITH PALYGORSKITEJuly 2024September 2024Allow210NoNo
18777712CELL ADHESION METHOD WITH SODIUM MONTMORILLONITEJuly 2024September 2024Allow210NoNo
18746792LAG-3 COMBINATION THERAPY FOR THE TREATMENT OF CANCERJune 2024September 2025Abandon1510NoNo
18740390INTERLEUKIN 18 (IL-18) VARIANTS AND FUSION PROTEINS COMPRISING SAMEJune 2024September 2024Allow301YesNo
18731223LIPID NANOPARTICLE FORMULATIONS AND COMPOSITIONSMay 2024January 2025Allow820YesNo
18668012COVALENT MULTI-SPECIFIC ANTIBODYMay 2024September 2024Allow400YesNo
18660672ANTIBODIES CAPABLE OF BINDING TO OX40, VARIANTS THEREOF AND USES THEREOFMay 2024April 2025Allow1111NoNo
18656081ANTIBODIES THAT BIND PSMA AND GAMMA-DELTA T CELL RECEPTORSMay 2024June 2025Allow1310NoNo
18656166ANTIBODIES TARGETING LIV-1 AND USES THEREOFMay 2024August 2024Allow300YesNo
18648976ANTIBODY AGAINST ADVANCED GLYCATION END PRODUCTS AND USE THEREOFApril 2024September 2024Allow500YesNo
18644963HYDROGEL PARTICLES AS FEEDER CELLS AND AS SYNTHETIC ANTIGEN PRESENTING CELLSApril 2024February 2026Abandon2231NoNo
18704212MOLECULAR MARKER FOR DETERMINING VERY-EARLY-STAGE ONSET RISK OF GASTRIC CANCER AND EVALUATING PROGRESSION RISK OF PRE-CANCEROUS LESION OF GASTRIC CANCER, AND USE THEREOF IN DIAGNOSTIC KITApril 2024October 2025Abandon1710NoNo
18640824COMPOSITION COMPRISING ANTIBODY THAT BINDS TO DOMAIN II OF HER2 AND ACIDIC VARIANTS THEREOFApril 2024August 2024Allow410NoNo
18638229BCMA CHIMERIC ANTIGEN RECEPTORS AND USES THEREOFApril 2024January 2025Allow911YesNo
18702095COLD ATMOPSHERIC PLASMA TREATED PAN-CANCER EPITOPE PEPTIDE WITHIN THE COLLAGEN TYPE VI A-3 (COL6A3) PROTEIN AS CANCER VACCINEApril 2024January 2026Abandon2130NoNo
18637283ADJUVANT TREATMENT OF HER2-POSITIVE BREAST CANCERApril 2024September 2024Allow510YesNo
18635426ANTIBODIES FOR IL-17CApril 2024February 2026Abandon2210NoNo
18699018COMPOSITION FOR PREVENTING OR TREATING AUTOIMMUNE DISEASESApril 2024December 2025Allow2031YesNo
18620025Antibody, Linkers, Payload, Conjugates and Applications ThereofMarch 2024October 2025Allow1860YesNo
18618414ANTI-HER2 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, AND CHIMERIC ANTIGEN RECEPTOR COMPRISING SAMEMarch 2024May 2025Allow1310NoNo
18618634METHODS OF TREATING COMPLEMENT-MEDIATED DISEASEMarch 2024January 2025Allow1021YesNo
18612767DIAGNOSTIC METHODS USING ANTI-MUC1* ANTIBODIESMarch 2024March 2025Allow1211YesNo
18612579MEMBRANE-BOUND IL-12 FOR CELLULAR IMMUNOTHERAPYMarch 2024June 2024Allow300YesNo
18596217ANTI-INFLUENZA NEURAMINIDASE MONOCLONAL ANTIBODIES AND USES THEREOFMarch 2024May 2025Allow1521NoNo
18593711SYSTEMS TARGETING PSMA AND CA9March 2024January 2025Allow1001YesNo
18590121BIOMARKERS AND METHODS OF TREATING PD-1 AND PD-L1 RELATED CONDITIONSFebruary 2024August 2025Abandon1701NoNo
18430961COMPOSITIONS AND METHODS FOR MODULATING CANCER IMMUNE FITNESSFebruary 2024January 2026Abandon2321NoNo
18423752ANTIBODIES TO PROGRAMMED CELL DEATH PROTEIN 1 THAT ARE PD-1 AGONISTSJanuary 2024April 2024Allow300YesNo
18424381METHOD AND COMPOSITION FOR INDUCING TOLERANCEJanuary 2024July 2025Abandon1820NoNo
18415608HETERODIMERIC ANTIBODIES THAT BIND PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AND CD3January 2024May 2025Allow1510NoNo
18411436ANTI-CD37 ANTIBODY-DRUG CONJUGATEJanuary 2024July 2024Allow601YesNo
18409191IMMUNOCOMPETENT CELL THAT EXPRESSES A CELL SURFACE MOLECULE SPECIFICALLY RECOGNIZING HUMAN MESOTHELIN, IL-7 AND CCL19January 2024December 2025Abandon2310NoNo
18409450GOUT FLARE PREVENTION METHODS USING IL-1BETA BLOCKERSJanuary 2024November 2024Allow1020YesNo
18405977BINDING MOLECULESJanuary 2024August 2024Allow800YesNo
18402252FIBROBLAST BINDING AGENTS AND USE THEREOFJanuary 2024November 2025Allow2220NoNo
18402596COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHYJanuary 2024April 2024Allow410YesNo
18394409METHODS OF TREATING A NEOPLASIA WITH IL-15-BASED MOLECULES AND CTLA-4 ANTIBODYDecember 2023June 2024Allow610YesNo
18573191THERAPEUTIC TARGETING OF CADHERIN 11 IN CANCERDecember 2023September 2025Allow2120YesYes
18393436VACCINIA VIRUS RECOMBINANT A33R PROTEIN AND KIT FOR DIAGNOSING ANTIBODIES AGAINST ORTHOPOXVIRUS COMPRISING THE SAMEDecember 2023November 2024Allow1110NoNo
18570249ANTI-PDL1 ANTIBODIES AND USES THEREOFDecember 2023March 2025Abandon1501NoNo
18570578ANTI-CD3 CONSTRUCTS AND USES THEREOFDecember 2023October 2024Allow1010YesNo
18528165METHODS AND IMMUNOGENIC COMPOSITIONS RELATING TO HER2 WITH SELECTIVE SEQUENCE MODIFICATIONSDecember 2023January 2026Allow2521NoNo
18526598IL-15-BASED FUSIONS TO IL-12 AND IL-18December 2023February 2024Allow301YesNo
18514019Cancer Cytotoxic Exosome Formulations and Methods for Use in Treating CancerNovember 2023June 2025Allow1920YesNo
18511591ANTI-B7H3 ANTIBODY-DRUG CONJUGATE AND USE THEREOFNovember 2023June 2024Allow710YesNo
18510412COMBINATION THERAPIES WITH BISPECIFIC ANTI-EGFR/C-MET ANTIBODIES AND THIRD GENERATION EGFR TYROSINE KINASE INHIBITORSNovember 2023June 2025Allow1920NoNo
18388099PROTEIN BIOMARKER AND USES THEREOFNovember 2023November 2025Allow2510NoNo
18503865Role of PVT1 in the Diagnosis and Treatment of MYC-Driven CancerNovember 2023December 2025Allow2530NoNo
18503564COMPOSITIONS AND METHODS FOR USING FIXED BIOLOGICAL SAMPLESNovember 2023July 2024Allow911NoNo
18501741DUAL CYTOKINE FUSION PROTEINS COMPRISING IL-10November 2023February 2024Allow401YesNo
18499484Cancer Stem Cell-Targeted Cancer TherapyNovember 2023August 2025Abandon2201NoNo
18490581PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST NON-SMALL CELL LUNG CANCER AND OTHER CANCERSOctober 2023August 2024Allow1010YesNo
18488634COMBINATION TREATMENT OF CD38-EXPRESSING TUMORSOctober 2023August 2025Abandon2201NoNo
18380117NUCLEIC ACID BIOMARKER AND USE THEREOFOctober 2023July 2025Allow2121YesNo
18484244METHODS AND COMPOSITIONS FOR DOSING OF ALLOGENEIC CHIMERIC ANTIGEN RECEPTOR T CELLSOctober 2023May 2024Allow710YesNo
18285649COMPOSITIONS AND METHODS FOR THE PREVENTION OR TREATMENT OF RHEUMATOID ARTHRITISOctober 2023August 2025Allow2230YesNo
18479619ANTIBODIES THAT BIND EGFR AND ERBB3October 2023January 2026Allow2721NoNo
18374956ENGINEERED IMMUNE CELLS TARGETING BCMA AND THEIR USES THEREOFSeptember 2023September 2025Allow2410YesNo
18469458PARTITIONING SYSTEMS AND METHODS FOR DETERMINING MULTIPLE TYPES OF CANCERSSeptember 2023November 2025Allow2641YesNo
18466103MAGE-A4 PEPTIDE DUAL T CELL ENGAGERSSeptember 2023July 2024Allow1011YesNo
18453404Anti-BCMA Antibody Drug Conjugate Combination Treatment for CancerAugust 2023October 2024Allow1410NoNo
18448947COMBINATION OF KYNURENINE AND ANTIGEN PRESENTING CELLS (APC) AS THERAPEUTICS AND METHODS FOR THEIR USE IN IMMUNE MODULATION IN THE TREATMENT OF ALOPECIA AREATIA (AA)August 2023December 2025Abandon2842YesNo
18448294METHODS FOR TREATING AN OCULAR CONDITION WITH CELLULAR FIBRONECTIN COMPOSITIONSAugust 2023January 2024Allow510NoNo
18446032ANTIBODIES BINDING TO CD3 and CD19August 2023September 2024Allow1401NoNo
18366183METHOD OF TREATING POST-TRAUMATIC STRESS DISORDERAugust 2023May 2025Allow2120YesNo
18366028ANTIBODY-IMMUNE AGONIST CONJUGATE AND APPLICATIONS THEREOFAugust 2023July 2025Allow2310NoNo
18363417CHIMERIC ANTIGEN RECEPTORS TARGETING ABNORMAL GLYCOBIOLOGYAugust 2023May 2025Allow2210NoNo
18225567PROTEIN-ANTIVIRAL COMPOUND CONJUGATESJuly 2023February 2025Allow1910YesNo
18355341METHODS OF TREATING HEMATOLOGICAL MALIGNANCY USING NANOPARTICLE MTOR INHIBITOR COMBINATION THERAPYJuly 2023November 2025Abandon2810NoNo
18272337PROTOCOL TO MINIMIZE CALCINEURIN INHIBITOR NEPHROTOXICITYJuly 2023May 2025Abandon2201NoNo
18351374MATERIALS AND METHODS FOR PERFORMING HISTOCHEMICAL ASSAYS FOR HUMAN PRO-EPIREGULIN AND AMPHIREGULINJuly 2023May 2025Allow2210YesNo
18349983ONCOLYTIC VIRUS VECTOR AND APPLICATION THEREOFJuly 2023March 2024Allow810YesNo
18346437AFFINITY MOLECULES AND METHODS FOR THEIR USEJuly 2023April 2024Allow901NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1646.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
102
Examiner Affirmed
75
(73.5%)
Examiner Reversed
27
(26.5%)
Reversal Percentile
19.6%
Lower than average

What This Means

With a 26.5% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
1338
Allowed After Appeal Filing
219
(16.4%)
Not Allowed After Appeal Filing
1119
(83.6%)
Filing Benefit Percentile
2.3%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 16.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Art Unit 1646 - Prosecution Statistics Summary

Executive Summary

Art Unit 1646 is part of Group 1640 in Technology Center 1600. This art unit has examined 12,640 patent applications in our dataset, with an overall allowance rate of 51.1%. Applications typically reach final disposition in approximately 33 months.

Comparative Analysis

Art Unit 1646's allowance rate of 51.1% places it in the 8% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.

Prosecution Patterns

Applications in Art Unit 1646 receive an average of 1.81 office actions before reaching final disposition (in the 43% percentile). The median prosecution time is 33 months (in the 35% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With fewer office actions than average, plan for relatively streamlined prosecution.
  • The median prosecution time is longer than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.